PACIRA BIOSCIENCES, INC. Repayments of Secured Debt
PACIRA BIOSCIENCES, INC. (PCRX) reported Repayments of Secured Debt of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSecuredDebt · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. repayments of secured debt for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. repayments of secured debt for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. repayments of secured debt for the quarter ending 2025-06-30 was $3.75M.
- PACIRA BIOSCIENCES, INC. repayments of secured debt for the quarter ending 2025-03-31 was $2.81M.
- PACIRA BIOSCIENCES, INC. repayments of secured debt for fiscal 2022 was $78.13M.
- PACIRA BIOSCIENCES, INC. repayments of secured debt for fiscal 2021 was $0.00.
- PACIRA BIOSCIENCES, INC. repayments of secured debt for fiscal 2020 was $0.00.
| Period end | Repayments of Secured Debt 3 month | Repayments of Secured Debt 6 month | Repayments of Secured Debt 9 month | Repayments of Secured Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | |||
| 2025-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $6.56M 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | $2.81M 10-Q · filed 2026-04-30 | |||
| 2023-03-31 | $296.88M 10-Q · filed 2023-05-03 | $356.25M derived: sum of 2 quarters · filed 2023-05-03 | $365.63M derived: sum of 3 quarters · filed 2023-05-03 | $375.00M derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-12-31 | $59.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $68.75M derived: sum of 2 quarters · filed 2023-02-28 | $78.13M derived: sum of 3 quarters · filed 2023-02-28 | $78.13M 10-K · filed 2023-02-28 |
| 2022-09-30 | $9.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $18.75M derived: sum of 2 quarters · filed 2022-11-03 | $18.75M 10-Q · filed 2022-11-03 | $18.75M derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-06-30 | $9.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $9.38M 10-Q · filed 2022-08-03 | $9.38M derived: sum of 3 quarters · filed 2023-05-03 | $9.38M derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 | $0.00 derived: sum of 2 quarters · filed 2023-05-03 | $0.00 derived: sum of 3 quarters · filed 2023-05-03 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-03 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |